Alligator Bioscience announced the appointment of Sumeet Ambarkhane, MD, as its Chief Medical Officer. In this role, Sumeet will provide medical leadership and direction in the development of Alligator's best-in-class preclinical and clinical pipeline, including Alligator's lead assets mitazalimab, a CD40 agonist currently in Phase II clinical development, and ATOR-1017, a 4-1BB agonist in Phase I. Sumeet is a seasoned professional with over 20 years of drug development experience in academia and in the biotechnology and pharmaceutical industries. Sumeet has a proven track record of advancing investigational medicines including immunotherapy-biologics, from early phases of development through regulatory approvals and adoption into clinical practice.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.112 SEK | +0.54% | -3.97% | +61.39% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+61.39% | 79.73M | |
+48.54% | 56.87B | |
+37.15% | 39.72B | |
-6.02% | 39.27B | |
-6.90% | 28.73B | |
+12.97% | 26.21B | |
-16.91% | 19.79B | |
+31.71% | 12.28B | |
+28.18% | 12.23B | |
+0.38% | 12.12B |
- Stock Market
- Equities
- ATORX Stock
- News Alligator Bioscience AB
- Alligator Bioscience Appoints Sumeet Ambarkhane as Chief Medical Officer